Printer Friendly

THERAGENICS REPORTS REVENUES AND EARNINGS FOR FIRST QUARTER OF 1993

 ATLANTA, May 12 /PRNewswire/ -- Theragenics Corp. (NASDAQ: THRX), an Atlanta-based cancer therapy company, announced today that, for the first quarter ended March 31, 1993, it achieved a net profit of $3,000,000, or $.26 per share, compared to a net profit of $505,000, or $.05 per share, compiled in the first quarter of 1992. This first quarter profit reflects a one-time positive earnings adjustment to reflect the mandated implementation of FASB-109 "Accounting for Income Taxes." FASB-109's impact decreased first quarter earnings by $78,000, or $.01 per share, but increased prior period earnings by $2,860,000, or $.25 per share, both of which were reflected in first quarter earnings.
 The company's net profit in the first quarter of 1993 before extraordinary credits and adjustments for changes in accounting principle was $140,000, or $.01 per share. This figure exceeds the $100,000, or $.01 per share, predicted by management in its last annual report for this quarter.
 Theragenics' revenues in the first quarter of 1993 were $1,117,000, which exceeds the $1,000,000 predicted in the same annual report. At that time management indicated both sales and net profits would be negatively affected until the company's new cyclotron facility came fully on line.
 In the first quarter of 1992, the company achieved net profits of $319,000, or $.03 per share, and sales of $1,204,000.
 Chris Jacobs, CEO and president, confirmed that the new production facility was now on-line and should be capable of supporting the forecasted sales growth for the remaining three quarters. She added, "Theragenics is in a strong position to achieve the significant increases in sales and profit which we have forecasted for the remaining three quarters of the year."
 Theragenics manufactures and markets TheraSeed, a nonsurgical, outpatient treatment which uses implanted Palladium 103 seeds to eradicate prostate cancer.
 THERAGENICS CORP.
 Consolidated Statement of Operations
 (Unaudited)
 Three months ended March 31 1993 1992
 Revenues $1,117,000 $1,204,000
 Net earnings before extraordinary
 credit and before cumulative effect
 of a change in accounting principle 140,000 319,000
 Extraordinary credit -- 186,000
 Cumulative effect on prior years
 of change in method of accounting
 principle 2,860,000 --
 Net earnings $3,000,000 $ 505,000
 Earnings per common share $.26 $.05
 Weighted average shares 11,718,838 11,139,018
 -0- 5/12/93
 /CONTACT: Bruce Smith, CFO of Theragenics, 404-381-8338; or Rick Eisenberg of Eisenberg Communications, 212-496-6828, for Theragenics/
 (THRX)


CO: Theragenics Corp. ST: Georgia IN: HEA SU: ERN

GK-LR -- NY025 -- 7447 05/12/93 09:56 EDT
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:May 12, 1993
Words:429
Previous Article:CUSTOMEDIX CORP. REPORTS THIRD QUARTER AND NINE MONTH FINANCIAL RESULTS FOR ITS 1993 FISCAL YEAR
Next Article:THERAGENICS ANNOUNCES EXECUTIVE APPOINTMENTS
Topics:


Related Articles
THERAGENICS ANNOUNCES THIRD QUARTER RESULTS; QUARTERLY PROFITS INCREASE NEARLY THREE-FOLD; REVENUES ALSO SOAR
THERAGENICS ANNOUNCES 1992 RESULTS; SALES INCREASE 58 PERCENT AND PROFITS DOUBLE; 1993 FORECAST SHOWS PROFITS UP 167 PERCENT
/C O R R E C T I O N -- THERAGENICS CORPORATION/
DIAGNOSTEK FIRST QUARTER FISCAL 1994 RESULTS
THERAGENICS ANNOUNCES SECOND QUARTER RESULTS
THERAGENICS ANNOUNCES THIRD QUARTER RESULTS
THERAGENICS REPORTS REVENUES AND EARNINGS FOR FIRST QUARTER OF 1994
THERAGENICS REPORTS SECOND QUARTER 1994 EARNINGS
IVAX ANNOUNCES 1994 THIRD QUARTER EARNINGS
FIRST QTR. REVENUES AND NET INCOME UP FOR THERAGENICS.

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters